Author(s):
Kishore Gaddam, Srinivas Kumbam, Trivikram Reddy Gundala, Surendranath Reddy Reddiwary, Gangi Reddy Nallagondu Chinna
Email(s):
kishore.gaddam@gmail.com
DOI:
10.52711/0974-360X.2021.00977 
Address:
Kishore Gaddam1*, Srinivas Kumbam1, Trivikram Reddy Gundala1, Surendranath Reddy Reddiwary1, Gangi Reddy Nallagondu Chinna2*
1Analytical Development, Hetero R&D, TSIE, Balanagar, Hyderabad, India.
2Department of Chemistry, Yogi Vemana University, Kadapa, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 11,
Year - 2021
ABSTRACT:
Obeticholic acid (OBE) is being used to treat primary biliary cirrhosis and cholangitis. An HPLC with refractive index detection method for eight process related substances of OBE was developed and verified for use in quality assurance laboratories for regular analysis. The separation and analysis were performed on YMC Triart C18 (3.0 µm particle size, 250 mm × 4.6 mm) column. Mobile phase employed consisted of 0.01N potassium phosphate buffer (3.0 ± 0.05 pH, set with 0.1% orthophosphoric acid) and acetonitrile at 45:55 (v/v) ratio. The method established for determination of eight impurities in OBE was validated and verified in keeping with International Council for Harmonisation guidelines. This method can be used for routine analysis of eight impurities in OBE bulk samples.
Cite this article:
Kishore Gaddam, Srinivas Kumbam, Trivikram Reddy Gundala, Surendranath Reddy Reddiwary, Gangi Reddy Nallagondu Chinna. Detection and Evaluation of process related impurities in Obeticholic Acid Drug material using HPLC Method. Research Journal of Pharmacy and Technology. 2021; 14(11):5618-4. doi: 10.52711/0974-360X.2021.00977
Cite(Electronic):
Kishore Gaddam, Srinivas Kumbam, Trivikram Reddy Gundala, Surendranath Reddy Reddiwary, Gangi Reddy Nallagondu Chinna. Detection and Evaluation of process related impurities in Obeticholic Acid Drug material using HPLC Method. Research Journal of Pharmacy and Technology. 2021; 14(11):5618-4. doi: 10.52711/0974-360X.2021.00977 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-11-2
REFERENCES:
1. Pilaniya K, Chandrawanshi HK, Pilaniya U, Manchandani P, Jain P, Singh N. Recent trends in the impurity profile of pharmaceuticals. Journal of Advanced Pharmaceutical Technology and Research, 2010; 1(3): 302‐310.
2. Poonam RS, Smita A, Dipti P, Saudagar RB. Review on guideline on elemental impurities. Asian Journal of Research in Chemistry, 2016; 9(5): 226-232.
3. Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility. AAPS PharmSciTech, 2011; 12 (4): 1248‐1263.
4. Alsante KM, Huynh-Ba K, Baertschi SW, et al. Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms. AAPS PharmSciTech, 2014; 15 (1): 198‐212.
5. Görög S. Drug safety, drug quality, drug analysis. Journal of Pharmaceutical and Biomedical Analysis, 2008; 48 (2): 247‐253.
6. Yogeshwar RM, Ramesh V, Kista RC, et al. A sensitive and selective GC-MS method for the determination of process related genotoxic impurities in esomeprazole magnesium. Asian Journal of Research in Chemistry, 2010; 3(2): 395-397.
7. Yogeshwar RM, Ramesh V, Kista RC, et al. The quantitative determination of process related genotoxic impurities in esomeprazole magnesium by GC-MS. Asian Journal of Research in Chemistry, 2011; 4(6): 898-901.
8. Subramanian G, Subramania NM, Byran G, Dhanabal SP. Liquid chromatography-mass spectrometric method for simultaneous estimation of apigenin and luteolin from Achillea millefolium Linn. Asian Journal of Research in Chemistry, 2016; 9(12): 629-632.
9. Hemchand S, Babu RRC, Annapurna MM. Separation, characterization and quantification of impurities and identification of stress degradants of cabazitaxel by RP-HPLC and LC-ESI-MS techniques. Research Journal of Pharmacy and Technology, 2018; 11(10): 4683-4698.
10. Pramadvara K, Annapurna MM. Separation, identification and quantification of process related impurities and stress degradants of gefitinib by LC-ESI-Q–TOF/MS. Research Journal of Pharmacy and Technology, 2018; 11(8): 3647-3657.
11. Pramadvara K, Annapurna MM. Separation, identification and quantification of process related impurities and stress degradants of olaparib by LC-ESI-Q-TOF-MS. Research Journal of Pharmacy and Technology, 2018; 11(8): 3718-3726
12. Maruthi R, Chandan RS, Anand KT. Characterization of impurities in teneligliptin hydrobromide hydrate by using LCMS/MS and NMR Research Journal of Pharmacy and Technology, 2020; 13(8): 3569-3576.
13. Chandana OSS, Babu RR. Method development and validation of valsartan and its impurities by high performance liquid chromatography. Asian Journal of Pharmaceutical Analysis, 2017; 7(2): 87-92.
14. Parvatamma B, Rao TN, Patrudu TB, Apparao K. A new high-performance liquid chromatographic method for identification and quantification of fosinopril sodium and its related impurities in bulk drug product. Asian Journal of Pharmaceutical Research, 2017; 7(3): 165-170.
15. Rao TN, Apparao K, Krishnarao N, Vijayalakshmi A. A new simultaneous HPLC analytical method for quantification of benazepril hydrochloride and its related impurities in bulk drug product. Asian Journal of Research in Pharmaceutical Sciences, 2017; 7(3): 135-140.
16. Mahalingam V, Vijayabaskar S, Kalaivani RA, Somanathan T. Analytical method development and validation for the analysis of donepezil hydrochloride and its related substances using ultra performance liquid chromatography. Research Journal of Pharmacy and Technology, 2017; 10(8): 2743-2749.
17. Mohammed K, Ghoufran K, Mohammad H, Mouhammad AR, Amir AS. Quantitative determination of albendazole forced degradation percentages by densitometric thin layer chromatographic method. Research Journal of Pharmacy and Technology, 2020; 13(5): 2207-2213.
18. ICH Expert Working Group. Impurities in new drug substances, Q3A (R2); (2006).
19. ICH Expert Working Group. Validation of Analytical Procedures: Text and Methodology, Q2 (R1); 2005.
20. European Medicines Agency, Impurities in new drug products, London, UK, Q3B (R2); 2006.
21. U.S. Department of Health and Human Services, Food and Drug Administration (FDA). Genotoxic and Carcinogenic Impurities in Drug Substances and Products. Rockville, MD; 2008.
22. Venkatesan P, Valliappan K. Impurity profiling: theory and practice. Journal of Pharmaceutical Sciences and Research, 2014; 6 (7): 254, 2014.
23. Manne V, Kowdley KV. Obeticholic acid in primary biliary cholangitis: where we stand. Current Opinion in Gastroenterology, 2019; 35 (3): 191-196.
24. Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs, 2016; 76(12): 1221-1226.
25. Michal D, Markéta S, Tomáš K, Josef Č, Petr G, Josef Z. HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control. Journal of Pharmaceutical and Biomedical Analysis, 2018; 149: 214-224.